Cytosorbents Corporation
CTSO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.05 | 0.12 | -0.01 |
| FCF Yield | 0.00% | -1.93% | -5.78% | -4.95% |
| EV / EBITDA | -27.33 | -30.21 | -21.63 | -6.62 |
| Quality | ||||
| ROIC | -8.80% | -9.35% | -9.36% | -8.76% |
| Gross Margin | 70.28% | 70.85% | 71.13% | 103.80% |
| Cash Conversion Ratio | -0.78 | 2.34 | 0.30 | 1.05 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.89% | 1.31% | 1.49% | 3.32% |
| Free Cash Flow Growth | 0.00% | 55.96% | -42.40% | 10.63% |
| Safety | ||||
| Net Debt / EBITDA | -6.85 | -5.25 | -4.37 | -2.13 |
| Interest Coverage | 4.44 | -5.87 | -6.42 | -6.48 |
| Efficiency | ||||
| Inventory Turnover | 0.70 | 0.76 | 0.83 | 0.09 |
| Cash Conversion Cycle | 101.34 | 82.61 | 68.14 | -119.40 |